Design and analysis considerations for early phase clinical trials in hepatitis B (HBV) cure research: the ACTG A5394 study in persons with both HIV and HBV

Hepatitis B surface antigen and Hepatitis B RNA changes in HIV/HBV Co-infected participants receiving HBV-active antiretroviral therapy for 144 weeks

(2022) Claudia Hawkins et al.   AIDS

Estimands: bringing clarity and focus to research questions in clinical trials

(2022) Timothy Peter Clark et al.   BMJ Open

Incorporating estimands into clinical trial statistical analysis plans

(2022) Minhee Kang et al.   Clinical Trials

The Use of External Controls in FDA Regulatory Decision Making

(2021) Mahta Jahanshahi et al.   Therapeutic Innovation & Regulatory Science

Estimands in published protocols of randomised trials: urgent improvement needed

(2021) Brennan C. Kahan et al.   Trials

Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States

(2021) Karine Dubé et al.   AIDS Research and Therapy

Prospects for the Global Elimination of Hepatitis B

(2021) Timothy M. Block et al.   Annual Review of Virology

Estimands in practice: Bridging the gap between study objectives and statistical analysis

(2020) Alan Phillips et al.   PHARMACEUTICAL STATISTICS

Single hepatocytes show persistence and transcriptional inactivity of hepatitis B

(2020) Ashwin Balagopal et al.   JCI Insight

Multi-stakeholder consensus on a target product profile for an HIV cure

(2020) Sharon R Lewin et al.   Lancet HIV

Liver safety assessment in clinical trials of new agents for chronic hepatitis B

(2019) Robert J. Fontana et al.   JOURNAL OF VIRAL HEPATITIS

Estimands in clinical trials - broadening the perspective

(2016) Mouna Akacha et al.   STATISTICS IN MEDICINE

Rates and determinants of hepatitis B ‘e’ antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus

(2015) Anders Boyd et al.   AIDS

Present and future therapies of hepatitis B: From discovery to cure

(2015) T. Jake Liang et al.   HEPATOLOGY

Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV-/HBV-coinfected patients

(2013) R. Strassl et al.   JOURNAL OF VIRAL HEPATITIS

Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals

(2013) Gail V. Matthews et al.   PLoS One

Hepatitis B Surface Antigen Declines and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV

(2012) R. Zoutendijk et al.   JOURNAL OF INFECTIOUS DISEASES